• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why ShiftPixy Surges Around 177%; Here Are 71 Biggest Movers From Yesterday

    9/9/22 4:13:55 AM ET
    $AEO
    $AGS
    $AKA
    $ALBO
    Clothing/Shoe/Accessory Stores
    Consumer Discretionary
    Miscellaneous manufacturing industries
    Consumer Discretionary
    Get the next $AEO alert in real time by email

    Gainers

    • ShiftPixy, Inc. (NASDAQ:PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
    • Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) gained 51% to settle at $27.03 after the FDA Advisory Committee voted that available evidence of effectiveness is sufficient to support approval of AMX0035 for the treatment of ALS. Citigroup and SVB Leerink raised their price targets.
    • Rubius Therapeutics, Inc. (NASDAQ:RUBY) climbed 48.6% to close at $1.29 after declining 11% on Wednesday. Rubius Therapeutics, last month, posted a Q2 loss of $0.49 per share.
    • Benitec Biopharma Inc. (NASDAQ:BNTC) shares gained 33% to close at $0.7880. The company, last week, filed its annual report on Form 10-K for the quarter ended June 30, 2022, with the U.S. Securities and Exchange Commission.
    • Marker Therapeutics, Inc. (NASDAQ:MRKR) rose 31.5% to close at $0.3999 after the company's Phase 2 study of multi-tumor-associated antigen-specific T cell therapy for relapsed/refractory AML appeared on the FDA's Orphan Products Grants Program site.
    • Palatin Technologies, Inc. (NYSE:PTN) gained 26.2% to close at $6.31 after the company announced the initiation of patient recruitment for its Phase 2 study evaluating oral PL8177 in ulcerative colitis.
    • LifeStance Health Group, Inc. (NASDAQ:LFST) jumped 25.8% to close at $9.57. LifeStance Health named Ken Burdick as CEO and Chairman.
    • T Stamp Inc. (NASDAQ:IDAI) gained 25% to settle at $1.85.
    • Asana, Inc. (NYSE:ASAN) shares gained 24.8% to close at $23.76 after the company reported better-than-expected results for its second quarter and issued a strong sales guidance. RBC Capital and Citigroup raised their price targets on the stock.
    • Relay Therapeutics, Inc. (NASDAQ:RLAY) gained 23.8% to close at $31.37. Relay Therapeutics announced efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients with a FGFR2-fusion or rearrangement FGFR inhibitor-naïve cholangiocarcinoma: ReFocus trial.
    • Revance Therapeutics, Inc. (NASDAQ:RVNC) gained 21.6% to close at $25.30 after the company announced FDA approval of DAXXIFY for injection for temporary improvement of moderate to severe frown lines.
    • SPAR Group, Inc. (NASDAQ:SGRP) rose 21.3% to close at $1.54 after the company's board of directors initiated a process to evaluate potential strategic alternatives including a sale, merger or other strategic transaction.
    • Allarity Therapeutics, Inc. (NASDAQ:ALLR) rose 20.4% to settle at $1.30.
    • Eve Holding, Inc. (NYSE:EVEX) jumped 20% to close at $7.39. United reported a $15 million investment in Eve Air Mobility and a conditional purchase agreement for 200 four-seat electric aircraft plus 200 options.
    • Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) climbed 18.9% to settle at $708.85 after the company announced that the primary endpoints were met in two pivotal trials investigating novel aflibercept 8 mg with 12- and 16-week dosing regimens in patients with diabetic macular edema and wet age-related macular degeneration.
    • Eyenovia, Inc. (NASDAQ:EYEN) gained 18.6% to close at $2.48.
    • VistaGen Therapeutics, Inc. (NASDAQ:VTGN) jumped 18.4% to close at $0.1953 after the company announced the completion of an interim analysis of its PALISADE-2 Phase 3 clinical trial of PH94B.
    • IVERIC bio, Inc. (NASDAQ:ISEE) gained 18.3% to settle at $17.68 after Stifel maintained a Buy rating on the stock and raised its price target from $28 to $35.
    • First High-School Education Group Co., Ltd. (NYSE:FHS) gained 17% to close at $0.75.
    • Lyft, Inc. (NASDAQ:LYFT) gained 16.9% to close at $17.17 amid vague rumors from a questionable source mentioning the company.
    • NantHealth, Inc. (NASDAQ:NH) jumped 16.4% to close at $0.4788.
    • Venus Concept Inc. (NASDAQ:VERO) gained 15.8% to close at $0.7473.
    • Annovis Bio, Inc. (NYSE:ANVS) climbed 15.7% to settle at $12.19 after HC Wainwright & Co initiated coverage on the stock with a Buy rating and announced a $40 price target.
    • Phreesia, Inc. (NYSE:PHR) rose 15.6% to close at $27.64 after the company reported better-than-expected Q2 sales results and raised the low-end of its FY23 sales guidance.
    • Tandem Diabetes Care, Inc. (NASDAQ:TNDM) jumped 15.3% to close at $52.61.
    • AeroVironment, Inc. (NASDAQ:AVAV) gained 14.9% to close at $101.87 after reporting upbeat quarterly sales.
    • Immunocore Holdings plc (NASDAQ:IMCR) rose 14.9% to settle at $57.44 after Ladenburg Thalmann initiated coverage on the stock with a Buy rating and announced an $82 price target.
    • Terns Pharmaceuticals, Inc. (NASDAQ:TERN) gained 14.7% to close at $4.36.
    • Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) rose 14.4% to close at $23.86. Rhythm Pharmaceuticals announced new employment inducement grants. Goldman Sachs maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $28 to $31.
    • Cazoo Group Ltd (NYSE:CZOO) gained 13.5% to close at $0.6921. The company announced it will wind down operations in mainland Europe to focus on core UK market.
    • PROCEPT BioRobotics Corporation (NASDAQ:PRCT) jumped 11.3% to close at $49.93.
    • Rivian Automotive, Inc. (NASDAQ:RIVN) gained 10.9% to close at $36.88 after the company and Mercedes-Benz Vans signed a Memorandum of Understanding for a strategic partnership.
    • John Wiley & Sons, Inc. (NYSE:WLY) gained 10.8% to settle at $46.08. CJS Securities upgraded John Wiley & Sons from Market Perform to Market Outperform.
    • Allego N.V. (NYSE:ALLG) rose 9.6% to close at $4.33. Allego recently announced first half financial results and 2022 revenue expectations.
    • Heliogen, Inc. (NYSE:HLGN) rose 9.5% to close at $2.42.
    • Albireo Pharma, Inc. (NASDAQ:ALBO) surged 9.4% to close at $18.23. Guggenheim initiated coverage on Albireo Pharma with a Buy rating and announced a price target of $55.
    • Snap Inc. (NYSE:SNAP) rose 9.3% to close at $12.53 on continued strength after a recent internal memo obtained by The Verge suggested the company is aiming to reach $6 billion in revenue and 450 million users by next year.
    • Intapp, Inc. (NASDAQ:INTA) rose 8.5% to close at $15.95 after the company reported better-than-expected Q4 results and issued guidance above estimates.
    • GameStop Corp. (NYSE:GME) rose 7.5% to close at $25.83 after the company reported better-than-expected earnings for its second quarter and also announced a partnership with cryptocurrency exchange FTX to bring more customers to the digital asset space.
    • Zillow Group, Inc. (NASDAQ:ZG) gained 6.3% to close at $37.58 after Jefferies maintained a Buy rating on the stock and raised its price target from $48 to $50.


    Losers

    • Troika Media Group, Inc. (NASDAQ:TRKA) dipped 26.8% to settle at $0.4756 on Thursday after declining around 6% on Wednesday.
    • Great Panther Mining Limited (NYSE:GPL) shares tumbled 25.9% to close at $0.2396. The company recently announced it has determined to file a notice of intention to make a proposal under the Bankruptcy and Insolvency Act, which will provide credit protection.
    • PlayAGS, Inc. (NYSE:AGS) shares fell 20.2% to close at $6.07.
    • Ensysce Biosciences, Inc. (NASDAQ:ENSC) fell 19.7% to close at $0.3313.
    • a.k.a. Brands Holding Corp. (NYSE:AKA) dipped 19.2% to close at $2.36.
    • Globalstar, Inc. (NYSE:GSAT) fell 18.9% to settle at $1.67 amid possible profit taking. The stock gained on Wednesday after the company announced it will be the satellite operator for Apple satellite-enabled services.
    • Biophytis S.A. (NASDAQ:BPTS) declined 17.7% to close at $0.9139. Biophytis recently announced top-line results from its phase 2-3 COVA clinical study evaluating Sarconeos in the treatment of COVID-19-related respiratory failure.
    • Golden Path Acquisition Corporation (NASDAQ:GPCO) fell 16.7% to close at $7.40.
    • VirnetX Holding Corp (NYSE:VHC) dipped 16.6% to close at $1.56.
    • Addentax Group Corp. (NASDAQ:ATXG) dropped 15.7% to settle at $5.22.
    • Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) fell 15.5% to close at $30.76.
    • Nogin, Inc. (NASDAQ:NOGN) declined 15.4% to close at $1.71.
    • Bilibili Inc. (NASDAQ:BILI) fell 15% to close at $20.07 following Q2 results.
    • Skillsoft Corp. (NYSE:SKIL) fell 14.9% to close at $2.29 after the company posted downbeat quarterly sales and authorized a $30 million share buyback.
    • Tandy Leather Factory Inc. (NASDAQ:TLF) fell 14.8% to close at $5.24 following uplisting of its stock.
    • Dave & Buster's Entertainment, Inc. (NASDAQ:PLAY) dropped 14.2% to close at $37.72. While the company reported better-than-expected Q2 results, operating income dropped from 2021 levels.
    • Innovid Corp. (NYSE:CTV) fell 13.9% to close at $3.17.
    • Genenta Science S.p.A. (NASDAQ:GNTA) fell 13.5% to close at $4.60.
    • Chembio Diagnostics, Inc. (NASDAQ:CEMI) shares fell 13% to close at $0.5449. Chembio Diagnostics filed for potential stock offering.
    • Cohn Robbins Holdings Corp. (NYSE:CRHC) dipped 12.8% to close at $7.96.
    • MasterCraft Boat Holdings, Inc. (NASDAQ:MCFT) fell 12.7% to close at $20.74. The company posted upbeat quarterly earnings, but issued weak FY23 forecast. MasterCraft Boat also sold its NauticStar business to Iconic Marine Group.
    • Mercer International Inc. (NASDAQ:MERC) dipped 12.5% to close at $14.07.
    • The Lovesac Company (NASDAQ:LOVE) dropped 12.4% to close at $26.18 following Q2 results.
    • Erasca, Inc. (NASDAQ:ERAS) fell 11.3% to close at $8.34. Erasca announced preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors.
    • Sylvamo Corporation (NYSE:SLVM) declined 9.8% to close at $36.50.
    • Sabre Corporation (NASDAQ:SABR) dropped 9.5% to close at $6.54 after Mizuho maintained a Neutral rating on the stock and lowered its price target from $8 to $7.
    • Mullen Automotive, Inc. (NASDAQ:MULN) fell 9.3% to close at $0.61 after the company announced it has acquired a 60% controlling interest in Bollinger Motors for $148.2 million in cash and stock.
    • American Eagle Outfitters, Inc. (NYSE:AEO) shares fell 8.7% to settle at $10.58 after the company reported worse-than-expected Q2 EPS results.
    • McCormick & Company, Incorporated (NYSE:MKC) fell 6.7% to close at $79.30. McCormick said it expects third-quarter FY22 sales to increase about 3% year-on-year and 6% in constant currency.
    • Wayfair Inc. (NYSE:W) fell 3.7% to close at $48.81 after the company reported a proposed offering of $600 million convertible senior notes.
    • Grid Dynamics Holdings, Inc. (NASDAQ:GDYN) fell 3.6% to close at $19.08 after the company priced its common stock offering of about 5.71 million shares at $17.50 per share.
    Get the next $AEO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEO
    $AGS
    $AKA
    $ALBO

    CompanyDatePrice TargetRatingAnalyst
    Snap Inc.
    $SNAP
    4/14/2026$7.00 → $6.00Hold
    Canaccord Genuity
    McCormick & Company Incorporated
    $MKC
    4/14/2026Neutral
    BTIG Research
    Asana Inc.
    $ASAN
    4/14/2026$7.00Overweight → Neutral
    Piper Sandler
    Bilibili Inc.
    $BILI
    4/13/2026$31.00Equal-Weight → Overweight
    Morgan Stanley
    Rivian Automotive Inc.
    $RIVN
    4/1/2026$14.00Underperform → Neutral
    DA Davidson
    Phreesia Inc.
    $PHR
    4/1/2026Mkt Outperform → Mkt Perform
    Citizens
    Asana Inc.
    $ASAN
    4/1/2026$7.00Underperform → Sector Perform
    RBC Capital Mkts
    Regeneron Pharmaceuticals Inc.
    $REGN
    3/31/2026$875.00Overweight
    Piper Sandler
    More analyst ratings

    $AEO
    $AGS
    $AKA
    $ALBO
    SEC Filings

    View All

    SEC Form 144 filed by Wayfair Inc.

    144 - Wayfair Inc. (0001616707) (Subject)

    4/23/26 4:15:19 PM ET
    $W
    Catalog/Specialty Distribution
    Consumer Discretionary

    SEC Form 6-K filed by Genenta Science S.p.A.

    6-K - Genenta Science S.p.A. (0001838716) (Filer)

    4/23/26 4:05:16 PM ET
    $GNTA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form DEFA14A filed by The Lovesac Company

    DEFA14A - Lovesac Co (0001701758) (Filer)

    4/23/26 7:16:17 AM ET
    $LOVE
    Other Specialty Stores
    Consumer Discretionary

    $AEO
    $AGS
    $AKA
    $ALBO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Kellogg Peter R bought $236,600 worth of shares (70,000 units at $3.38) (SEC Form 4)

    4 - MERCER INTERNATIONAL INC. (0001333274) (Issuer)

    3/10/26 1:18:16 PM ET
    $MERC
    Paper
    Basic Materials

    Director Desai Antal Rohit bought $10,482,943 worth of shares (426,262 units at $24.59) (SEC Form 4)

    4 - PROCEPT BioRobotics Corp (0001588978) (Issuer)

    3/9/26 7:19:42 PM ET
    $PRCT
    Medical/Dental Instruments
    Health Care

    Director Flatley Jay T bought $25,281 worth of shares (1,830 units at $13.81) and sold $11,775 worth of shares (580 units at $20.30), increasing direct ownership by 0.78% to 162,070 units (SEC Form 4)

    4 - Rivian Automotive, Inc. / DE (0001874178) (Issuer)

    3/5/26 5:10:12 PM ET
    $RIVN
    Auto Manufacturing
    Industrials

    $AEO
    $AGS
    $AKA
    $ALBO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Canaccord Genuity reiterated coverage on Snap with a new price target

    Canaccord Genuity reiterated coverage of Snap with a rating of Hold and set a new price target of $6.00 from $7.00 previously

    4/14/26 1:08:30 PM ET
    $SNAP
    Computer Software: Programming Data Processing
    Technology

    BTIG Research initiated coverage on McCormick

    BTIG Research initiated coverage of McCormick with a rating of Neutral

    4/14/26 8:24:09 AM ET
    $MKC
    Packaged Foods
    Consumer Staples

    Asana downgraded by Piper Sandler with a new price target

    Piper Sandler downgraded Asana from Overweight to Neutral and set a new price target of $7.00

    4/14/26 8:14:22 AM ET
    $ASAN
    Computer Software: Prepackaged Software
    Technology

    $AEO
    $AGS
    $AKA
    $ALBO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    February 28, 2025 - FDA Roundup: February 28, 2025

    For Immediate Release: February 28, 2025 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:On Thursday, the FDA approved Odactra to include use in individuals 5 through 11 years of age to treat house dust mite induced nasal inflammation (allergic rhinitis), with or without eye inflammation (conjunctivitis). Odactra is an allergen extract immunotherapy

    2/28/25 5:00:47 PM ET
    $TNDM
    Medical/Dental Instruments
    Health Care

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    $AEO
    $AGS
    $AKA
    $ALBO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Sheehan Kevin M

    4 - Dave & Buster's Entertainment, Inc. (0001525769) (Issuer)

    4/23/26 4:30:02 PM ET
    $PLAY
    Restaurants
    Consumer Discretionary

    Director Bessler Robert sold $35,758 worth of shares (5,101 units at $7.01) (SEC Form 4)

    4 - LifeStance Health Group, Inc. (0001845257) (Issuer)

    4/23/26 4:25:41 PM ET
    $LFST
    Medical/Nursing Services
    Health Care

    SEC Form 4 filed by Chief Human Relations Officer Piper Sarah

    4 - MCCORMICK & CO INC (0000063754) (Issuer)

    4/23/26 3:37:17 PM ET
    $MKC
    Packaged Foods
    Consumer Staples

    $AEO
    $AGS
    $AKA
    $ALBO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

    Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with Merck's pending acquisition of Terns Pharmaceuticals, Inc. ("Terns") (NASDAQ:TERN) expired at 11:59 p.m., Eastern Time, on April 23, 2026. As previously announced on April 7, 2026, Merck commenced, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns, for $53.00 net in cash for each share of Terns common stock validly tendered and not validly withdrawn in the offer, without interest and less any applicable tax withholding. The ex

    4/24/26 6:45:00 AM ET
    $MRK
    $TERN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Mercer International Inc. Announces Conference Call for First Quarter 2026 Results

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ:MERC) will release its first quarter results for the period ending March 31, 2026 on Thursday, April 30, 2026, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 1, 2026, at 10:00 am ET to discuss the results. The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/ha9u4g4a A link to the webcast is also available o

    4/23/26 4:30:00 PM ET
    $MERC
    Paper
    Basic Materials

    Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.

    Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha), its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices in other developed countries; prices for future medicines in the U.S. will be aligned with prices set in that defined group of other countries Praluent® (alirocumab), an important cardiovascular medicine, will be available for direct patient purchase through TrumpRx.gov Regeneron will continue its large investment in domestic R&D and manufacturing capacity TARRYTOWN, N.Y., April 23, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced an

    4/23/26 3:46:16 PM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $AKA
    $ALBO
    Leadership Updates

    Live Leadership Updates

    View All

    AV Appoints Sean Woodward as Chief Financial Officer

      AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Sean T. Woodward as Executive Vice President and Chief Financial Officer, effective May 1, 2026. Woodward succeeds Kevin McDonnell, who will be stepping down from the role, as announced earlier this year. McDonnell will remain with the Company in an advisory role through July 2026 to help ensure a smooth transition of responsibilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260412005321/en/Sean Woodward is a seasoned finance leader with more than 22 years of experience in defense technology, including at A

    4/13/26 8:00:00 AM ET
    $AVAV
    Aerospace
    Industrials

    AV Appoints Dr. Robert Smith as Chief Operating Officer

    Defense Veteran to Strengthen Operational Execution as AV Scales Manufacturing and Supply Chain Capabilities AeroVironment, Inc. ("AV") (NASDAQ:AVAV), a global defense technology leader, today announced the appointment of Dr. Robert (Rob) Smith as Executive Vice President and Chief Operating Officer, effective April 13, 2026. In this role, Dr. Smith will oversee the Company's Autonomous Systems (AxS) and Space, Cyber and Directed Energy (SCDE) business units, as well as the Company's global operations and manufacturing footprint. His appointment reflects AV's continued focus on scaling manufacturing to meet rising customer demand, strengthening operational execution and enhancing capabi

    4/9/26 9:10:00 AM ET
    $AVAV
    Aerospace
    Industrials

    Rhythm Pharmaceuticals Announces Changes to Board of Directors

    -- Kim Popovits appointed as new Director; Ed Mathers to depart -- BOSTON, April 03, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced changes to its Board of Directors, including the appointment of Kim Popovits and the departure of Ed Mathers. "We are thrilled to welcome Kim to our Board of Directors," said David Meeker, M.D., Chairman, President and Chief Executive Officer of Rhythm. "Kim brings decades of leadership experience across biotechnology, diagnostics and commercial innovation, with a proven track record

    4/3/26 9:00:00 AM ET
    $RYTM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $AKA
    $ALBO
    Financials

    Live finance-specific insights

    View All

    Mercer International Inc. Announces Conference Call for First Quarter 2026 Results

    NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Mercer International (NASDAQ:MERC) will release its first quarter results for the period ending March 31, 2026 on Thursday, April 30, 2026, after the close of the market. Juan Carlos Bueno, President and Chief Executive Officer and Richard Short, Chief Financial Officer and Secretary, will be hosting a conference call on Friday, May 1, 2026, at 10:00 am ET to discuss the results. The conference call will be available to interested parties live over the Internet through a webcast by clicking on or copying and pasting the following link into their web browser: https://edge.media-server.com/mmc/p/ha9u4g4a A link to the webcast is also available o

    4/23/26 4:30:00 PM ET
    $MERC
    Paper
    Basic Materials

    Lyft Expands in London with Gett UK Acquisition

    Key takeaways: Lyft has agreed to acquire Gett's United Kingdom business with close expected in the coming weeks, subject to customary closing conditions. Gett is one of London's leading black cab apps with strong enterprise business-to-business (B2B) relationships, and brings together the majority of Greater London's registered black cab drivers and will nearly double the number of rides on the Lyft platform in London. With Gett, Lyft is expanding its coverage of London's full ground transport ecosystem. This advances Lyft's sustainable global growth strategy, while expanding "out" in more locations and "up" into more high-value segments. Lyft (NASDAQ:LYFT) has agreed to acq

    4/23/26 8:48:00 AM ET
    $LYFT
    Real Estate

    Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial

    As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application submitted; cemdisiran could be the first siRNA to be approved for the treatment of gMG Regeneron to host virtual ‘Regeneron Roundtable: gMG & C5 Complement Program' investor event on Wednesday, April 22 at 8:30 a.m. ET TARRYTOWN, N.Y., April 21, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced detailed positive results from the Phase 3 NIMBLE trial evaluating investigational cemdisiran in adults with generalized myasthenia gravis (gMG) w

    4/21/26 10:30:00 AM ET
    $REGN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEO
    $AGS
    $AKA
    $ALBO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Benitec Biopharma Inc.

    SC 13G/A - Benitec Biopharma Inc. (0001808898) (Subject)

    12/6/24 1:47:28 PM ET
    $BNTC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Eyenovia Inc.

    SC 13D/A - EYENOVIA, INC. (0001682639) (Subject)

    12/4/24 4:12:20 PM ET
    $EYEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lyft Inc.

    SC 13G/A - Lyft, Inc. (0001759509) (Subject)

    12/4/24 2:38:58 PM ET
    $LYFT
    Real Estate